Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Organon by Quarter
Organon — Jada System (postpartum hemorrhage device) International sales ($M) ($M)
Merck Organon: $0M in Q2 2026. That is the highest of the 16 quarters on record here.
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
11
Documents cited below
Where the Q2 2026 figure comes from
Source: Organon & Co. SEC Filing (0001628280-26-051230) ↗
Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Organon ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-jada-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.